ECGI Holdings Inc (ECGI)

[Potse]

January 2015 executive summary.....

From the January 20, 2015 executive summary placed on the ECGI website last week.....

ECGI has partnered with Contex Canada Inc., & Ceres Technologies Inc. to design and build the new computer-controlled line that provides full automation of the processing from raw materials through final packaged product, with the capability of printing in any language. The proprietary processes and system will create significant savings in manufacturing costs.

Contex & Ceres are leaders in the Semiconductor, Nanotechnology & Biotechnology industries.

When at full production capacity the line will be capable of producing approximately 2.5 million complete pairs of BreastCare DTS™ per year with one shift and 5 million units with two shifts. Additional production lines will be added as backlog of sales demands. The phase one of the production plan will be a hand assembly production line with limited capacity to provide finished
BreastCare DTS™ devices for government registrations and samples while the full production line is built out.

Current market research indicates a retail price point in the United States for BreastCare DTS™ at $39.95. At this price, we anticipate gross margins in the 73 to 78% range. The wholesale price will be adjusted based on individual contract parameters. ECGI anticipates selling 756,000 units in Year One revenues of $18 MM with Profits of $6.6 MM; 5,449,000 units in Year Two with revenues of $116 MM with Profits of $50 MM and 13,788,000 units in Year Three with revenues of $283 MM with Profits of $154 MM based on production ramp-up and current sales discussions and projections. 75% of the sales are projected to be outside the US in Year One and 65% every year after.

BreastCare DTS™ is to be used in US physician offices during patient visits as a screening device for breast abnormalities as part of a woman’s annual examination. It is then to be used by the woman six months later if she is not in a high-risk group, and every three months if she is in a high-risk group. It is not intended to replace mammography and other detection methods, but to be used as an adjunct to other screening methods.

ECGI intends to implement sales in the US with multi-prong program that leverages several components. An ECGI sales force will target identified specific groups of physicians, some of which are considered leaders in the breast cancer segment of the medical industry. In addition to a sales force, the Company will develop an in-house sales capability for physicians interested in purchasing the product directly. A combination of the Physician’s Awareness Program, and leveraging a consumer education program with a targeted public relations and marketing campaign will be coordinated and leveraged to launch the BreastCare DTS™ device in the US. The Company also has interest from medical distribution companies for US medical and hospital distribution under consideration.

http://www.eventcardiogroup.com/about-ecgi/mission/

http://www.eventcardiogroup.com/wp-content/uploads/2014/12/Executive_Summary.pdf